Status:
COMPLETED
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
Epilepsy Foundation
Conditions:
Epilepsy
Psychiatric or Mood Diseases or Conditions
Eligibility:
FEMALE
18-50 years
Brief Summary
Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate. The purpo...
Eligibility Criteria
Inclusion
- Women ages 18-50 years inclusive who are taking valproate or lamotrigine for neurologic or psychiatric conditions
- Valproate of lamotrigine must be used as monotherapy at stable doses for 6 weeks prior to the study for the neurologic or psychiatric illness; medications taken for other reasons are not excluded.
Exclusion
- Women with prior exposure to valproate or lamotrigine if they are taking lamotrigine or valproate respectively.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01231646
Start Date
October 1 2010
End Date
July 1 2015
Last Update
November 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
North Shore Long Island Jewish Health System
Great Neck, New York, United States, 11021